Novartis

An open book with pages turning on a wooden table set

Erasca looks to partner off late-stage melanoma asset

The asset, which Erasca picked up from Novartis for $20 million, would be the first targeted therapy in NRASm melanoma if it were to make it to market.

Gabrielle Masson May 13, 2025 10:38am

PTC and Novartis’ Huntington's data fail to convince investors

May 6, 2025 7:25am

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

Apr 30, 2025 9:30am

Novartis axes osteoarthritis asset and radioligand therapy

Apr 29, 2025 5:24am

X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm

A closer look at pharma's top R&D budgets

Apr 4, 2025 9:34am